ReviewInternational journal of molecular sciences2026
Proteomic Changes in Patients with LADA-Type Diabetes: Prospects for Diagnostic Biomarkers.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Latent autoimmune diabetes in adults (LADA) is a form of diabetes with clinical and biological features overlapping those of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), which may complicate early diagnosis and disease classification. Interest in proteomic and related biomarker profiles in LADA has increased in recent years because these markers may improve understanding of its pathophysiology and support more accurate differentiation from other forms of diabetes. This narrative review provides a structured overview of currently available evidence on selected inflammatory, immunological, and metabolic biomarkers associated with LADA. The reviewed literature includes data on adiponectin, IFN-γ, CCL2/MCP-1, IL-6, GPLD1, and other markers potentially linked to immune dysregulation, low-grade inflammation, and progressive β-cell dysfunction. Several studies suggest that LADA may present an intermediate biomarker profile, with some features overlapping with T1DM and others with T2DM. At the same time, the available evidence remains heterogeneous and is limited mainly by small sample sizes, cross-sectional designs, and incomplete clinical validation. Therefore, although several biomarkers appear promising for further investigation, their current role should be regarded as exploratory rather than established for routine clinical use. Further longitudinal and well-characterized studies are needed to determine whether selected biomarker patterns may eventually contribute to improved identification and stratification of LADA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.